Mitiglinide

Mitiglinide
Clinical data
Trade names	Glufast
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth (tablets)
ATC code	A10BX08 (WHO) ;
Identifiers
	IUPAC name (−)-(2S,3a,7a-cis)-α-Benzylhexahydro-γ-oxo-2-isoindolinebutyric acid;
CAS Number	145375-43-5 ;
PubChem CID	121891;
DrugBank	DB01252 ;
ChemSpider	108739 ;
UNII	D86I0XLB13;
KEGG	D01854 ;
ChEMBL	ChEMBL471498 ;
CompTox Dashboard (EPA)	DTXSID4048303 ;
Chemical and physical data
Formula	C19H25NO3
Molar mass	315.413 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3;
	InChI InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 ; Key:WPGGHFDDFPHPOB-BBWFWOEESA-N ;
	(what is this?) (verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Mitiglinide (INN,^[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.^[2]

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium K_ATP channels in pancreatic β cells.

Dosage

Mitiglinide is delivered in tablet form.

References

^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.
^ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opinion on Pharmacotherapy. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455. S2CID 73318104.

External links

Elixir Pharmaceuticals — website of the U.S. rights holder for mitiglinide.

[INN-1] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.

[pmid18803455-2] Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opinion on Pharmacotherapy. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455. S2CID 73318104.

[1]

[2]